284. Diamond-Blackfan anemia Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 36 Drugs : 95 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 126

Drugs and their primary sponsors and trial info
(S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo   
   Shire Development LLC
      2010   Phase 2   EUCTR2010-019645-25-GB   Italy;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide   
   Shire Development LLC
      2010   Phase 2   EUCTR2010-019645-25-GB   Italy;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m   
   Shire Development LLC
      2012   Phase 2   EUCTR2011-006322-25-GB   Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
(S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide   
   Shire Development LLC
      2012   Phase 2   EUCTR2011-006322-25-GB   Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Abatacept   
   Emory University
      2014   Phase 1   NCT01917708   United States;
Alefacept   
   Emory University
      2010   -   NCT01319851   United States;
Alemtuzumab   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03653338   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
Allogeneic bone marrow transplantation   
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Allogeneic hematopoietic stem cell transplantation   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
Alpha beta depletion   
   Mitchell Cairo
      2020   Phase 2   NCT04099966   United States;
Anti-thymocyte globulin   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States;
      1999   -   NCT00290628   United States;
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States;
Antithymocyte globulin   
   National Heart, Lung, and Blood Institute (NHLBI)
      1998   Phase 2   NCT00001749   United States;
BPX-501 T cells   
   Bellicum Pharmaceuticals
      2014   Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States;
Bone marrow transplantation   
   Stanford University
      2009   Phase 2   NCT00957931   United States;
Busulfan   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States;
      1999   -   NCT00290628   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Busulfan, Cyclophosphamide, ATG, GCSF   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States;
Busulfan, Fludarabine, ATG, TLI   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States;
CD3/CD19 depleted leukocytes   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03653338   United States;
CD34 Stem Cell Selection Therapy   
   Diane George
      2013   Phase 1/Phase 2   NCT01966367   United States;
CD45RA depleted leukocytes   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03653338   United States;
Campath, Fludarabine, Cyclophosphamide   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States;
Cyclophosphamide   
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States;
Cyclophosphamide Dose Level 1   
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide Dose Level 2   
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide Dose Level 3   
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide Dose Level 4   
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclosporine   
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      1998   Phase 2   NCT00001749   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
DFO   
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
Daclizumab   
   Neal Young, M.D.
      1999   Phase 2   NCT00001962   United States;
Deferasirox   
   Novartis
      2007   Phase 4   NCT00673608   Australia;
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
   Novartis Pharmaceuticals
      2005   Phase 3   NCT00235391   Australia;Belgium;Canada;Germany;Greece;Italy;Netherlands;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Deferitazole   
   Shire Development LLC
      2012   Phase 2   EUCTR2011-006322-25-GB   Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Deferoxamine   
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
Desferal   
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
Eltrombopag   
   National Heart, Lung, and Blood Institute (NHLBI)
      2020   Phase 1/Phase 2   NCT04269889   United States;
Enriched Hematopoetic Stem Cell Infusion   
   Talaris Therapeutics Inc.
      2011   Phase 1/Phase 2   NCT01419704   United States;
FBS0701 CAPSULE   
   FERROKIN BIOSCIENCES INC.
      2012   -   EUCTR2011-006322-25-IT   Italy;United Kingdom;United States;
      2012   -   EUCTR2011-005675-16-IT   Canada;Italy;Lebanon;Turkey;United States;
FBS0701 Capsule   
   FERROKIN BIOSCIENCES INC.
      2010   -   EUCTR2010-019645-25-IT   Italy;United Kingdom;
FBS0701/SSP004184   
   FERROKIN BIOSCIENCES INC.
      2012   -   EUCTR2011-006322-25-IT   Italy;United Kingdom;United States;
Filgrastim   
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States;
Fludarabine   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03653338   United States;
Fludarabine monophosphate   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States;
Fludarabine phosphate   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
G-CSF   
   National Heart, Lung, and Blood Institute (NHLBI)
      2001   Phase 2   NCT00011505   United States;
Human Placental Derived Stem Cell   
   New York Medical College
      2013   Phase 1   NCT01586455   United States;
Hydroxyurea   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03653338   United States;
ICL670   
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
Iron chelating agents   
   FERROKIN BIOSCIENCES INC.
      2012   -   EUCTR2011-005675-16-IT   Canada;Italy;Lebanon;Turkey;United States;
L-leucine   
   Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache
      2014   Phase 2   NCT02386267   Russian Federation;
Lenalidomide   
   Jason Robert Gotlib
      2009   Phase 1   NCT01034592   United States;
Leucine   
   Northwell Health
      2013   Phase 1/Phase 2   NCT01362595   United States;
Leukapheresis   
   National Heart, Lung, and Blood Institute (NHLBI)
      2001   Phase 2   NCT00011505   United States;
Melphalan   
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Mesenchymal Stromal Cells   
   Stanford University
      2009   Phase 2   NCT00957931   United States;
Methotrexate   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
Methylprednisolone   
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
Mycophenolate mofetil   
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Myeloablative Preparative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
Peripheral blood stem cell transplantation   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;
Radiation therapy   
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States;
Reduced Intensity Preparative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
Reduced Toxicity Ablative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
Rimiducid   
   Bellicum Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03733249   Italy;Saudi Arabia;United Kingdom;
      2014   Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States;
Rituximab   
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00229619   United States;
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03653338   United States;
Rivogenlecleucel   
   Bellicum Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03733249   Italy;Saudi Arabia;United Kingdom;
SSP-004184 100 mg Capsule   
   Shire Development LLC
      2010   Phase 2   EUCTR2010-019645-25-GB   Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 250 mg Capsule   
   Shire Development LLC
      2010   Phase 2   EUCTR2010-019645-25-GB   Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 375 mg Capsule   
   Shire Development LLC
      2010   Phase 2   EUCTR2010-019645-25-GB   Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 50 mg Capsule   
   Shire Development LLC
      2010   Phase 2   EUCTR2010-019645-25-GB   Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184 500 mg Capsule   
   Shire Development LLC
      2010   Phase 2   EUCTR2010-019645-25-GB   Italy;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 100 mg Capsule   
   Shire Development LLC
      2012   Phase 2   EUCTR2011-006322-25-GB   Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 200 mg Capsule   
   Shire Development LLC
      2012   Phase 2   EUCTR2011-006322-25-GB   Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 250 mg Capsule   
   Shire Development LLC
      2012   Phase 2   EUCTR2011-006322-25-GB   Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 375 mg Capsule   
   Shire Development LLC
      2012   Phase 2   EUCTR2011-006322-25-GB   Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
SSP-004184AQ 50 mg Capsule   
   Shire Development LLC
      2012   Phase 2   EUCTR2011-006322-25-GB   Canada;Egypt;Italy;Lebanon;Thailand;Turkey;United Kingdom;United States;
Sotatercept with prednisone boost   
   Northwell Health
      2012   Phase 1/Phase 2   NCT01464164   United States;
Stem cell infusion   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States;
Stem cell transplant   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States;
Tacrolimus   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Thiotepa   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03653338   United States;
Thiotepa--escalated dose   
   University of Florida
      2018   Phase 1/Phase 2   NCT03513328   United States;
Thiotepa--single daily dose   
   University of Florida
      2018   Phase 1/Phase 2   NCT03513328   United States;
Total lymphoid irradiation   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States;
Trifluoperazine   
   Adrianna Vlachos
      2019   Phase 1/Phase 2   NCT03966053   United States;
Umbilical cord blood transplantation   
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States;
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States;
      2000   Phase 1/Phase 2   NCT00305708   United States;